https://idataresearch.com/wp-content/themes/lambda-child-theme/images/footer-logo.png
https://idataresearch.com/wp-content/themes/lambda-child-theme/images/idata-white-logo.png

Immunology

The immunology drugs market size is growing steadily and with biosimilars already beginning to affect the market it will become more active. As the population ages and more people are looking for effective drugs for a host of maladies, the scope of immunology drugs market research is expanding at a significant rate.

Click Here to Learn About Our Global Capabilities in Immunology Drugs Market Research

Markets included within immunology drugs includes: Crohn’s Disease Drug Market, Rheumatoid Arthritis Drug Market, Psoriasis Drug Market, Ulcerative Colitis Drug Market, and the Ankylosing Spondylitis Drug Market. iData Research has done extensive immunology drugs market analysis to give you access to important and accurate market trends. Our reports let you know exactly where you should direct your efforts.

Showing 1–16 of 24 results

Ulcerative Colitis Drug Market Analysis | Europe | 2018-2024 | MedCore

This market report includes a detailed analysis of the drugs used to treat ulcerative colitis in Europe, including Entyvio, Humira, Remicade, and Simponi. The ulcerative colitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

more...

Immunology Drugs Market Overview | Europe | 2018-2024 | MedView

The Europe immunology market includes biologic drugs that are used in the treatment of various immunology diseases such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn`s disease (CD), ulcerative colitis (UC) and psoriasis (PsO). As there is a need for cost effective drugs in treating these diseases, there is an increased number of drugs in development for these diseases. Current treatment mainly constitutes NSAIDs and biologics.

more...

Ulcerative Colitis Drug Market Analysis | Europe | 2018-2024 | MedCore

This market report includes a detailed analysis of the drugs used to treat ulcerative colitis across the globe (12 countries), including Entyvio, Humira, Remicade, and Simponi. The ulcerative colitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

more...

Psoriasis Drug Market Analysis | Europe | 2018-2024 | MedCore

This market report includes a detailed analysis of the drugs used to treat psoriasis across the globe (12 countries), including Humira, Enbrel, Remicade, and Stelera. The psoriasis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

more...

Rheumatoid Arthritis Drug Market Analysis | Europe | 2018-2024 | MedCore

This market report includes a detailed analysis of the drugs used to treat rheumatoid arthritis across the globe (12 countries), including Orencia, Humira, Cimzia, Enbrel, Simponi, Remicade, Rituxan, Actemra, and Xeljanz. The rheumatoid arthritis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

more...

Ankylosing Spondylitis Drug Market Analysis | Europe | 2018-2024 | MedCore

This market report includes a detailed analysis of the drugs used to treat ankylosing spondylitis across the globe (12 countries), including Humira, Cimzia, Enbrel, Simponi, and Remicade. The ankylosing spondylitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

more...

Crohn’s Disease Drug Market Analysis | Europe | 2018-2024 | MedCore

This market report includes a detailed analysis of the drugs used to treat Crohn's disease across the globe (12 countries), including Humira, Cimzia, Remicade, Stelara, Entyvio, and Tysabri. The Crohn's disease drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

more...

Ulcerative Colitis Drug Market Analysis | Brazil | 2018-2024 | MedCore

This market report includes a detailed analysis of the drugs used to treat ulcerative colitis outside the U.S. and Europe, including Entyvio, Humira, Remicade, and Simponi. The ulcerative colitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

more...

Psoriasis Drug Market Analysis | Brazil | 2018-2024 | MedCore

This market report includes a detailed analysis of the drugs used to treat psoriasis outside the U.S. and Europe, including Humira, Enbrel, Remicade, and Stelera. The psoriasis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

more...

Rheumatoid Arthritis Drug Market Analysis | Brazil | 2018-2024 | MedCore

This market report includes a detailed analysis of the drugs used to treat rheumatoid arthritis outside the U.S. and Europe, including Orencia, Humira, Cimzia, Enbrel, Simponi, Remicade, Rituxan, Actemra, and Xeljanz. The rheumatoid arthritis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

more...

Ankylosing Spondylitis Drug Market Analysis | Brazil | 2018-2024 | MedCore

This market report includes a detailed analysis of the drugs used to treat ankylosing spondylitis outside the U.S. and Europe, including Humira, Cimzia, Enbrel, Simponi, and Remicade. The ankylosing spondylitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

more...

Crohn’s Disease Drug Market Analysis | Brazil | 2018-2024 | MedCore

This market report includes a detailed analysis of the drugs used to treat Crohn’s disease outside the U.S. and Europe, including Humira, Cimzia, Remicade, Stelara, Entyvio, and Tysabri. The Crohn’s disease drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

more...

Immunology Drugs Market Overview | United States | 2018-2024 | MedView

The U.S. immunology market includes biologic drugs that are used in the treatment of various immunology diseases such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn`s disease (CD), ulcerative colitis (UC) and psoriasis (PsO). As there is a need for cost effective drugs in treating these diseases, there is an increased number of drugs in development for these diseases. Current treatment mainly constitutes NSAIDs and biologics. However, this report is limited to biologics, as they constitute 90% of the revenue in immunology. The reports covers second line treatments, their dosage, comparative cost studies, market size and revenue forecasts.

more...

Ulcerative Colitis Drug Market Analysis | United States | 2018-2024 | MedCore

This market report includes a detailed analysis of the drugs used to treat ulcerative colitis in the US, including Entyvio, Humira, Remicade, and Simponi. The ulcerative colitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

more...

Immunology Drugs Product Portfolio and Pipeline | United States | 2018-2024 | MedFolio

The Immunology Drug Product Portfolio contains Drug Classifications, Product Assessment, Data by Company, Price Analysis by Retail and Veteran Discounts for biologics such as ORENCIA®, HUMIRA®, CIMZIA®, Enbrel®, SIMPONI®, REMICADE®, RITUXAN®, Actemra®, STELARA®, ENTYVIO® and TYSABRI®.

more...

Psoriasis Drug Market Analysis | United States | 2018-2024 | MedCore

This market report includes a detailed analysis of the drugs used to treat psoriasis in the US, including Humira, Enbrel, Remicade, and Stelera. The psoriasis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

more...